Ro CEO Zach Reitano talks launch of Wegovy's GLP-1 pill

Watch on YouTube ↗  |  January 06, 2026 at 23:13  |  4:49  |  CNBC
Speakers
Zach Reitano — Co-Founder and CEO, Ro

Summary

Zach Reitano, Co-Founder and CEO of Ro, discusses the launch of Novo Nordisk's oral Wegovy GLP-1 pill. He describes strong demand, $149 first-dose pricing, injectable-matched efficacy, and a 48-hour diagnosis-to-delivery pathway via Ro. He argues the oral format will expand the total GLP-1 market by attracting needle-hesitant, injection-fatigued, and GLP-1-curious patients rather than simply cannibalizing injectables.

  • Novo Nordisk's oral Wegovy GLP-1 pill has launched with Ro as a telehealth partner.
  • Ro reports tremendous demand and a 48-hour diagnosis-to-delivery process.
  • The pill starts at $149 for the first dose, down sharply from prior injectable pricing.
  • Zach says the oral version matches injectable weight-loss efficacy.
  • He expects the oral launch to massively expand the GLP-1 market.
  • The addressable pool includes needle-phobic, injection-fatigued, and GLP-1-curious patients.
  • He expects injectables to remain relevant for higher-BMI patients.
  • The interview ends with a question about potential Eli Lilly talks.
Ideas
Zach Reitano Co-Founder and CEO, Ro 0:34
Strong demand for Novo oral Wegovy
Ro is seeing tremendous demand for Novo Nordisk's oral Wegovy GLP-1 pill, which launched as the first direct-to-consumer GLP-1 on day one. The pill starts at $149 for the first dose versus roughly $1,300 previously, matches injectable weight-loss efficacy, and enables diagnosis-to-delivery in 48 hours or less, making it a major positive for Novo Nordisk's obesity franchise.
NVO HIGH
Zach Reitano Co-Founder and CEO, Ro 0:44
Oral GLP-1s should see broad adoption
The oral GLP-1 format should be a major commercial opportunity because it removes needle hesitancy and injection fatigue, is cheaper and less intimidating than injectables, and can attract maintenance patients who prefer a pill. It is already seeing demand from needle-phobic, injection-fatigued, and GLP-1-curious patients.
Oral GLP-1 drugs HIGH
Zach Reitano Co-Founder and CEO, Ro 1:19
GLP-1 market should massively expand
Zach expects the oral GLP-1 launch to massively expand the total GLP-1 market rather than just cannibalize injectables. The key driver is the large pool of GLP-1-curious patients—tens of millions who have been on the sidelines—plus lower $149 pricing, pill convenience, same weight-loss efficacy, and reduced stigma around prescription weight loss.
OZEM HIGH
Up Next
2:00:47
A VERDADE POR TRÁS DO ATAQUE AMERICANO À VENEZUELA (com Professor HOC) | Market Makers #307
Market Makers · Jan 06
17:53
ETF Edge: The 2026 ETF Playbook - What investors can expect
CNBC · Jan 06
14:20
Three key ETF investing themes to watch in 2026
CNBC · Jan 06
3:46
Where crypto ETFs could be headed in 2026
CNBC · Jan 06
5:27
Evercore ISI's Amit Daryanani shares his bull case for the data storage stocks
CNBC · Jan 06

This CNBC video, published January 06, 2026, features Zach Reitano discussing NVO, Oral GLP-1 drugs, OZEM. 3 trade ideas extracted by AI with direction and confidence scoring.

Speakers: Zach Reitano  · Tickers: NVO, Oral GLP-1 drugs, OZEM